SQUAWK/NEWS
Account
Theme
Account
Menu
Live News NEWS FLASH L impact

Weekly Recap: HC Wainwright $38 target and advances two ctDNA MRD programs

HC Wainwright lifted its price target on Biodesix, Inc. (NASDAQ:BDSX) to $38 from $27, citing a richer diagnostics multiple and confidence in the company’s MRD testing strategy as BDSX advances tumor—informed and tumor—naïve ctDNA programs with Bio—Rad and Thermo Fisher toward MSK validation and pa…

BDSX

Related stories